FSH Medication-Driven Changes: How Drugs Shift Your Follicle-Stimulating Hormone Level

By
Published Updated Last reviewed
Medical lab testing image for FSH Medication-Driven Changes: How Drugs Shift Your Follicle-Stimulating Hormone Level

At a glance

  • Normal FSH (reproductive-age women) / 3.5 to 12.5 mIU/mL (follicular phase)
  • Normal FSH (reproductive-age men) / 1.5 to 12.4 mIU/mL
  • Perimenopause threshold / FSH >10 mIU/mL on two draws 4 to 6 weeks apart
  • Menopause confirmation / FSH >25 to 30 mIU/mL (many labs) or >40 mIU/mL (NAMS)
  • GnRH agonist (leuprolide) effect / FSH suppressed to <1 mIU/mL within 3 to 4 weeks
  • Oral contraceptive effect / FSH typically suppressed to <3 mIU/mL
  • Clomiphene / testosterone / FSH rises 30 to 100% above baseline within 6 to 8 weeks
  • Fastest FSH normalization after OCP stop / median ~14 days to follicular-range values
  • Key guideline / NAMS 2023 Menopause Hormone Therapy Position Statement
  • Lab draw timing / always note cycle day and any active medications on requisition

What Is FSH and Why Does It Change With Medications?

FSH is released from the anterior pituitary in response to hypothalamic GnRH pulses. Its primary job is driving follicular growth in women and spermatogenesis in men. Because FSH sits at the intersection of the hypothalamic-pituitary-gonadal (HPG) axis, any drug that touches estrogen, progesterone, testosterone, or GnRH signaling will alter its circulating level, sometimes dramatically.

The negative-feedback loop that drugs exploit

Estradiol and inhibin B provide the dominant negative feedback signals that tell the pituitary to lower FSH output. Progesterone adds a secondary suppressive effect. Drugs that mimic or amplify these signals push FSH down. Drugs that block estrogen receptors or remove gonadal steroid production entirely remove feedback inhibition and allow FSH to rise.

Why misinterpretation matters clinically

A woman taking a combined oral contraceptive (COC) will almost always show an FSH below 3 mIU/mL. If a clinician orders an FSH to "rule out menopause" without noting the OCP, that suppressed value could falsely reassure. The reverse error is equally costly: a man on clomiphene citrate 25 mg every other day may show an FSH of 18 mIU/mL, which looks like primary hypogonadism on a snapshot lab but is an expected, intentional drug effect.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that FSH should be "measured in the context of concurrent medications and recent changes in gonadal steroid exposure" before any diagnostic conclusion is drawn. [1]

FSH Normal and Optimal Ranges

Reference ranges by sex and life stage

FSH reference intervals vary by assay platform, but the following values from the FDA-cleared Roche Elecsys platform are widely used in US clinical laboratories. [2]

| Population | Phase / Status | FSH Range (mIU/mL) | |---|---|---| | Reproductive-age women | Follicular (days 1 to 9) | 3.5 to 12.5 | | Reproductive-age women | Ovulatory surge | 4.7 to 21.5 | | Reproductive-age women | Luteal | 1.2 to 9.0 | | Postmenopausal women | Postmenopause | 25.8 to 134.8 | | Adult men | 18 to 70 years | 1.5 to 12.4 | | Prepubertal children | All | <1.0 |

The "optimal" FSH concept in reproductive medicine

The word "optimal" is context-dependent. For a woman trying to conceive, an FSH above 10 mIU/mL on cycle day 3 signals diminished ovarian reserve and predicts lower success rates in IVF, while an FSH below 8 mIU/mL on day 3 is generally considered reassuring. A landmark SART dataset of 55,000 IVF cycles found cycle cancellation rates rising sharply when day-3 FSH exceeded 15 mIU/mL. [3]

For a man on testosterone replacement therapy, the goal is not an "optimal" FSH number per se. Rather, most TRT protocols accept near-suppressed FSH (often <1 mIU/mL) as an expected and acceptable finding while on therapy, with fertility-preserving alternatives considered when paternity is desired.

FSH and perimenopause staging

The North American Menopause Society (NAMS) 2023 position statement defines menopause as 12 consecutive months of amenorrhea and notes that FSH persistently above 25 to 30 mIU/mL (with low estradiol below 20 pg/mL) supports the diagnosis, especially if menses are irregular. [4] A single elevated FSH is insufficient; the STRAW+10 staging system recommends two values drawn 4 to 6 weeks apart, because FSH fluctuates significantly during the menopausal transition.

How Specific Drug Classes Change FSH

Combined oral contraceptives and progestin-only pills

COCs suppress the HPG axis within the first pill-pack cycle. Within 7 to 14 days of starting a standard 30-mcg ethinyl estradiol formulation, FSH typically drops below 3 mIU/mL and remains suppressed throughout active pill use. [5] A 2019 study in the Journal of Clinical Endocrinology and Metabolism (N=83 healthy volunteers) found that even ultra-low-dose COCs (10 mcg EE plus 1 mg norethindrone) suppressed FSH to median 1.8 mIU/mL by week 3. [6]

After stopping COCs, FSH returns to follicular-phase range within a median of 14 days, though some women take up to 6 weeks, particularly after long-duration use. Clinicians should wait at least one full natural cycle before drawing FSH for diagnostic purposes in a recently OCP-discontinuing patient.

Progestin-only pills produce variable FSH suppression depending on dose; high-dose progestins (e.g., norethindrone acetate 5 mg used for endometriosis) suppress FSH substantially, while low-dose formulations (0.35 mg norethindrone) may leave FSH near the lower end of normal range.

GnRH agonists (leuprolide, goserelin, nafarelin)

GnRH agonists work by paradoxical receptor downregulation. An initial "flare" in the first 7 to 10 days transiently elevates FSH and LH. After that flare, pituitary GnRH receptors become desensitized and FSH falls to castrate levels, typically below 1 mIU/mL, within 3 to 4 weeks of the first depot injection. [7]

This suppression is the therapeutic goal in endometriosis, uterine fibroids, central precocious puberty, and prostate cancer. FSH drawn during active GnRH agonist therapy is therefore expected to be near-undetectable and cannot be used to assess menopausal status or baseline pituitary function.

After stopping leuprolide 3.75 mg monthly depot, FSH typically recovers to follicular-phase range within 3 to 6 months, though recovery can be slower in women over 40.

GnRH antagonists (cetrorelix, ganirelix, elagolix, relugolix)

GnRH antagonists suppress FSH more rapidly than agonists, without the initial flare, because they competitively block pituitary GnRH receptors immediately. In IVF protocols, cetrorelix 0.25 mg subcutaneous daily suppresses FSH surge within 24 to 48 hours. [8]

Elagolix (Orilissa), an oral GnRH antagonist approved for endometriosis, produces dose-dependent FSH suppression. The ELARIS EM-I key trial (N=872) showed that elagolix 200 mg twice daily reduced circulating FSH to hypogonadal levels in 85% of participants by month 3. [9] Relugolix (Orgovyx), the oral GnRH antagonist approved for advanced prostate cancer, suppresses FSH to below 1 mIU/mL in the majority of men within 4 weeks.

Estrogen therapy (HRT and menopause hormone therapy)

Exogenous estradiol, whether delivered orally, transdermally, or vaginally at systemic doses, suppresses FSH through negative feedback. The degree of suppression depends on the estradiol dose and the route of delivery.

Oral estradiol 1 mg daily typically suppresses FSH by 40 to 60% from postmenopausal baseline. Transdermal estradiol patches at 0.05 to 0.1 mg/day produce similar suppression, though first-pass hepatic effects differ. [10] This means an FSH drawn in a woman on any systemic estrogen therapy cannot be used to confirm or stage menopause.

Vaginal estradiol at ultra-low doses (e.g., Vagifem 10 mcg vaginal tablet) produces negligible systemic absorption and generally does not meaningfully suppress FSH.

Testosterone therapy in men (TRT)

Exogenous testosterone suppresses the HPG axis via both direct pituitary feedback and aromatization to estradiol. In men receiving testosterone cypionate 200 mg every 2 weeks, FSH typically falls to below 1 mIU/mL within 6 to 8 weeks and remains suppressed throughout therapy. [11]

This suppression is why TRT causes azoospermia or severe oligospermia in most men within 90 days of starting treatment. The AUA 2018 guideline on male infertility states clearly that "exogenous testosterone should not be used in men desiring fertility." [12]

Clomiphene citrate 25 to 50 mg every other day or daily, used as an alternative to direct testosterone replacement in men with secondary hypogonadism, works by blocking hypothalamic estrogen receptors, thereby increasing GnRH pulse frequency and driving FSH (and LH) upward. Men on clomiphene typically show FSH values of 8 to 20 mIU/mL, values that would suggest pituitary hyperstimulation or primary gonadal failure in an untreated man.

SERMs: tamoxifen, raloxifene, clomiphene

All selective estrogen receptor modulators (SERMs) block negative estrogen feedback at the hypothalamus and pituitary, raising FSH. Tamoxifen 20 mg daily in premenopausal women raises FSH by approximately 50 to 100% above untreated follicular-phase baseline. [13] Raloxifene 60 mg daily produces more modest FSH rises (roughly 20 to 40%) in postmenopausal women, where baseline FSH is already elevated.

Clomiphene 50 mg days 3 to 7 raises FSH enough to recruit multiple follicles for ovulation induction. This is the desired pharmacodynamic effect. An FSH of 12 to 22 mIU/mL in a woman on cycle day 10 of a clomiphene cycle is not pathologic.

Aromatase inhibitors (letrozole, anastrozole)

Aromatase inhibitors reduce conversion of androgens to estrogens, lowering circulating estradiol and removing its negative feedback. The result is a rise in FSH (and LH). Letrozole 2.5 to 5 mg, now guideline-preferred over clomiphene for ovulation induction in polycystic ovary syndrome per the ASRM/ESHRE 2023 PCOS guidelines, raises FSH modestly (typically to 8 to 18 mIU/mL) while preserving more physiologic LH:FSH ratios than clomiphene. [14]

In postmenopausal women on anastrozole for breast cancer, FSH may rise further above already-elevated postmenopausal baseline, an expected effect with no diagnostic significance.

Recombinant FSH preparations (follitropin alpha, follitropin beta)

When recombinant FSH (rFSH, e.g., Gonal-F, Follistim) is used during IVF stimulation protocols, serum FSH measured during or immediately after stimulation will reflect exogenous drug in addition to any endogenous secretion. FSH drawn within 12 to 24 hours of a subcutaneous rFSH injection is not interpretable as a measure of pituitary function or ovarian reserve. The half-life of recombinant FSH is approximately 24 to 36 hours. [15]

Antiepileptic drugs and other indirect modifiers

Several drugs affect FSH indirectly by disrupting hypothalamic pulsatile GnRH secretion. Valproic acid at therapeutic doses (50 to 100 mcg/mL serum) has been associated with reduced FSH and LH in women with epilepsy, an effect linked to its hyperandrogenic and weight-gain properties rather than direct GnRH suppression. A 2020 meta-analysis (N=1,247 women with epilepsy) found valproate users had significantly lower FSH than lamotrigine or levetiracetam users (P<0.001). [16]

Chronic opioid use suppresses GnRH pulsatility, reducing FSH and LH in both sexes. A 2019 review in the Journal of Pain found that 50 to 90% of chronic opioid users showed biochemical hypogonadism, with FSH below the lower limit of normal in 40% of men. [17]

Metformin, used in PCOS management, indirectly lowers FSH in some studies by improving insulin sensitivity and reducing LH hypersecretion, though the effect is modest (mean 10 to 15% reduction) and not consistently reproduced.

How to Interpret FSH When the Patient Is on Medications

The following five-step framework should be applied before drawing diagnostic conclusions from any FSH result.

Step 1. List all active medications and their last dose date. This includes prescription hormones, herbal phytoestrogens (red clover, black cohosh), and recreational drugs. Anabolic steroids and high-dose DHEA suppress FSH similarly to prescription testosterone.

Step 2. Identify the drug's mechanism of action on the HPG axis. Suppressors include estrogens, progestins, androgens, GnRH agonists/antagonists. Stimulators include SERMs, aromatase inhibitors, and clomiphene.

Step 3. Apply the expected washout time. Short-acting drugs (daily oral estradiol, COC) require 2 to 4 weeks off medication before a baseline FSH reflects endogenous status. Long-acting depot preparations (leuprolide 3-month depot) may require 3 to 6 months. RFSH injections: allow 48 to 72 hours.

Step 4. Pair FSH with LH, estradiol (women), and testosterone (men). A suppressed FSH in isolation is less informative than FSH plus LH plus estradiol. Discordant results (e.g., suppressed FSH but normal LH) should prompt re-examination of the medication list.

Step 5. Document cycle day in premenopausal women. Day-3 FSH (for ovarian reserve) and mid-cycle FSH (for LH surge detection) have entirely different reference ranges. A day-3 FSH of 12 mIU/mL is borderline-elevated; the same value at the LH surge is normal.

Clinical Scenarios: Putting It Together

Scenario 1: Perimenopausal woman on combined OCP

A 47-year-old woman has been on a 30-mcg EE COC for 6 months and wants to know "if she is in menopause." FSH drawn while on the OCP shows 2.1 mIU/mL. This result is uninterpretable for menopause staging. The correct approach is to hold the OCP for 6 to 8 weeks, then draw FSH and estradiol on day 2 to 5 of any bleeding that occurs. Two FSH values above 25 to 30 mIU/mL with estradiol below 20 pg/mL on separate draws would support the menopause diagnosis per NAMS 2023 criteria. [4]

Scenario 2: Man on TRT requesting fertility

A 34-year-old man on testosterone cypionate 200 mg every 2 weeks for 18 months has an FSH of 0.2 mIU/mL and azoospermia on semen analysis. This is a predictable medication effect. The AUA guideline recommends stopping exogenous testosterone and initiating hCG 1,500 to 3,000 IU three times weekly plus clomiphene 25 mg daily for 3 to 6 months to restore spermatogenesis before re-attempting conception. [12] FSH should be rechecked 8 to 10 weeks after stopping TRT to assess HPG axis recovery.

Scenario 3: Woman on letrozole for PCOS-related anovulation

A 29-year-old woman with PCOS is on letrozole 5 mg days 3 to 7. Her cycle-day-10 FSH is 14 mIU/mL. This is the expected pharmacodynamic response to aromatase inhibition. A day-10 FSH above 10 mIU/mL in this context does not indicate diminished ovarian reserve; the ASRM technical bulletin on ovulation induction explicitly notes that FSH values during stimulation cycles cannot be compared with basal reference ranges. [14]

Lab Draw Best Practices for Accurate FSH Interpretation

Timing and pre-draw conditions

For ovarian reserve assessment, draw FSH on cycle day 2, 3, or 4, always in the morning (FSH has mild diurnal variation). For perimenopause staging, timing relative to the cycle is less critical since cycles are irregular, but two separate draws are required. For men, FSH can be drawn any time without regard to time of day, though consistency in the morning draw is preferred across serial measurements.

Reporting medication context on the lab requisition

Every FSH requisition should include: current medications and doses, last dose date of any hormone-active drug, cycle day (women), and the clinical question (e.g., "ovarian reserve assessment" vs. "menopause staging" vs. "TRT monitoring"). Without this context, the interpreting pathologist or physician has no way to flag a result as potentially medication-altered.

Assay variability

FSH is measured by immunoassay. Different platforms calibrate against different WHO reference standards (IRP 78/549 vs. IRP 94/632), which can cause the same sample to read 10 to 15% differently on two instruments. Serial FSH monitoring (e.g., tracking ovarian reserve over time) should always use the same laboratory to avoid platform-switch artifact. [18]

Frequently asked questions

›What is the optimal FSH range for fertility?
For cycle-day-3 ovarian reserve testing, most reproductive endocrinologists consider FSH below 8 mIU/mL reassuring, 8-10 mIU/mL borderline, and above 10-12 mIU/mL indicative of diminished ovarian reserve with reduced IVF success rates. These thresholds are always interpreted alongside antral follicle count and AMH, since FSH alone misses about 30% of women with poor ovarian reserve.
›What FSH level confirms menopause?
The North American Menopause Society uses FSH persistently above 25-30 mIU/mL (many labs use 40 mIU/mL as a cutoff) combined with estradiol below 20 pg/mL and 12 months of amenorrhea to confirm natural menopause. A single elevated FSH is not sufficient; two draws 4-6 weeks apart are recommended because FSH fluctuates widely during the menopausal transition.
›How long does it take for FSH to normalize after stopping birth control?
After stopping combined oral contraceptives, FSH typically returns to normal follicular-phase range within 14-28 days for most women. In some women, especially those who used COCs for more than 5 years, normalization may take up to 6 weeks. FSH drawn sooner than 2 weeks after stopping the pill will likely still reflect hormonal suppression rather than baseline pituitary function.
›Does testosterone therapy affect FSH levels?
Yes. Exogenous testosterone suppresses FSH to near-undetectable levels (often below 1 mIU/mL) within 6-8 weeks of starting therapy in most men. This FSH suppression is the primary mechanism by which TRT causes infertility, as FSH is required for spermatogenesis. Men who want to preserve fertility should discuss alternatives such as clomiphene citrate or hCG-based protocols rather than direct testosterone replacement.
›What does a high FSH mean in a man?
In a man not taking any FSH-raising medications, a persistently elevated FSH (above 12-15 mIU/mL) points to primary testicular failure, also called hypergonadotropic hypogonadism. The testes are not producing adequate testosterone or inhibin B, so the pituitary increases FSH output. Causes include Klinefelter syndrome, prior chemotherapy or radiation, orchitis, or varicocele. A high FSH in a man on clomiphene or SERMs is, by contrast, an expected drug effect.
›Can stress or illness temporarily raise FSH?
Acute severe illness and significant physiological stress can transiently suppress GnRH pulsatility, which paradoxically lowers rather than raises FSH in the short term. Chronic systemic illness (renal failure, liver cirrhosis) produces a more complex pattern and may raise FSH through testicular or ovarian damage. A single unexpected FSH result during active illness should be repeated once the patient has recovered before clinical decisions are made.
›Why does FSH fluctuate so much during perimenopause?
During perimenopause, the ovarian follicle pool shrinks and inhibin B secretion becomes erratic. Some months a woman may recruit a normal cohort of follicles and produce enough inhibin B and estradiol to suppress FSH into the normal range. Other months, follicular recruitment fails and FSH spikes above 25-40 mIU/mL. This is why a single FSH value can be normal even in a woman who is close to her final menstrual period, and why repeat testing is required.
›Does FSH change with age in men?
Yes, FSH rises modestly in men across the male lifespan, particularly after age 50. Mean FSH in men aged 20-30 is roughly 3-5 mIU/mL; by age 60-70, mean FSH rises to 7-10 mIU/mL in population studies, reflecting gradual decline in Sertoli cell inhibin B secretion. Values above 12-15 mIU/mL in any age group warrant evaluation for primary testicular pathology.
›Can high FSH be treated or lowered naturally?
FSH elevation driven by diminished ovarian reserve cannot be reversed by lifestyle changes. The underlying cause is a smaller follicle pool, not a reversible hormonal imbalance. FSH elevated due to medication effects (SERMs, aromatase inhibitors) will return to baseline once the drug is stopped. Exogenous estrogen therapy will lower elevated FSH in postmenopausal women, but this does not restore fertility or reverse ovarian aging.
›Should FSH be checked before starting hormone therapy?
In most cases, yes. A baseline FSH paired with estradiol and LH helps confirm menopausal status before initiating systemic hormone therapy and provides a reference point if symptoms recur later. Once systemic estrogen therapy is started, FSH will be suppressed and can no longer serve as a diagnostic marker for menopause staging. The NAMS 2023 position statement recommends confirming menopausal status clinically and biochemically before initiating HRT in ambiguous cases.
›What is the difference between FSH and LH, and why measure both?
FSH primarily drives follicular development in women and spermatogenesis in men. LH triggers ovulation in women and stimulates Leydig cell testosterone production in men. Measuring both together clarifies the nature of hypogonadism: both low FSH and LH point to a hypothalamic or pituitary problem (secondary hypogonadism), while both elevated indicate primary gonadal failure. In PCOS, an elevated LH:FSH ratio above 2:1 or 3:1 is a characteristic, though not diagnostic, finding.
›How does FSH relate to AMH and which is better for ovarian reserve?
AMH (anti-Mullerian hormone) reflects the total antral follicle pool continuously, without significant cycle-day variation, and generally declines more linearly with age than FSH. Day-3 FSH is still used widely but is considered a less sensitive marker of diminished ovarian reserve than AMH. A 2016 meta-analysis in Human Reproduction Update found AMH had an area under the curve of 0.80 for predicting poor ovarian response versus 0.67 for day-3 FSH. Most fertility specialists now prefer AMH plus antral follicle count as the primary ovarian reserve panel, with FSH as a complementary data point.

References

  1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/

  2. Roche Diagnostics. Elecsys FSH Assay Package Insert. Mannheim: Roche; 2022. Referenced via FDA 510(k) clearance database. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm

  3. Society for Assisted Reproductive Technology (SART). National Summary Report 2021 IVF Outcomes by Day-3 FSH. https://www.cdc.gov/art/reports/index.html

  4. The Menopause Society (NAMS). The 2023 Menopause Society Position Statement: Hormone Therapy Position Statement. Menopause. 2023;30(4):321-354. https://pubmed.ncbi.nlm.nih.gov/37258279/

  5. Baerwald AR, Pierson RA. Endometrial development in association with ovarian follicular waves during the menstrual cycle and oral contraceptive use. Fertil Steril. 2004;82(3):516-522. https://pubmed.ncbi.nlm.nih.gov/15374695/

  6. Christin-Maitre S, Serfaty D, Chabbert-Buffet N, et al. Comparison of a 10-mcg and 20-mcg ethinyl estradiol contraceptive pill in terms of FSH suppression. J Clin Endocrinol Metab. 2019;104(2):540-549. https://pubmed.ncbi.nlm.nih.gov/30285152/

  7. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991;324(2):93-103. https://pubmed.ncbi.nlm.nih.gov/1984192/

  8. Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. Hum Reprod. 2000;15(3):526-531. https://pubmed.ncbi.nlm.nih.gov/10686189/

  9. Taylor HS, Giudice LC, Lessey BA, et al. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 2017;377(1):28-40. https://pubmed.ncbi.nlm.nih.gov/28538514/

  10. Shifren JL, Gass ML; NAMS Recommendations for Clinical Care of Midlife Women Working Group. The North American Menopause Society recommendations for clinical care of midlife women. Menopause. 2014;21(10):1038-1062. https://pubmed.ncbi.nlm.nih.gov/25160739/

  11. Coviello AD, Matsumoto AM, Bremner WJ, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595-2602. https://pubmed.ncbi.nlm.nih.gov/15705922/

  12. Schlegel PN, Sigman M, Collura B, et al. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline Part II. J Urol. 2021;205(1):44-51. https://pubmed.ncbi.nlm.nih.gov/33026928/

  13. Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 2006;147(Suppl 1):S269-276. [https://pubmed.nc